GID.AX - GI Dynamics, Inc.

ASX - ASX Delayed price. Currency in AUD
0.031
-0.004 (-11.429%)
At close: 2:27PM AEDT
Stock chart is not supported by your current browser
Previous close0.035
Open0.032
Bid0.031 x 5347700
Ask0.032 x 9700000
Day's range0.031 - 0.032
52-week range0.020 - 0.085
Volume210,506
Avg. volume125,329
Market cap17.29M
Beta3.16
PE ratio (TTM)N/A
EPS (TTM)-0.022
Earnings date31 Mar. 2017 - 1 Apr. 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.03
  • Business Wire4 days ago

    GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics ® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier ® in Europe, the Middle East and South America for patients with type 2 diabetes ...

  • Business Wire9 days ago

    GI Dynamics Receives CE Certificate of Conformity Withdrawal Notice for EndoBarrier

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America has received notification from its notified body SGS United Kingdom, Limited (SGS) that SGS will withdraw the CE Certificate of Conformity for EndoBarrier effective 12 November 2017. As previously announced, on 17 May 2017 the company received notification from SGS that the EndoBarrier CE Certificate of Conformity was being suspended pending resolution of nonconformances related to ISO 13485 compliance.

  • Business Wire2 months ago

    IK+EM Study Released at EASD Shows Similar Outcomes Between Gastric Plication and EndoBarrier

    LISBON, Portugal--(BUSINESSWIRE)-- GI Dynamics ® , Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier ® in Europe, the Middle East and South America for patients with type 2 diabetes ...

  • Business Wire3 months ago

    GI Dynamics Appoints Juliet Thompson to Company’s Board of Directors

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics® Inc. (ASX:GID.AX - News), a medical device company that commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announces the appointment of medical and financial markets veteran Juliet Thompson to the company’s board of directors, effective immediately. Thompson has assumed the role of non-executive director (NED) and the role of chair of the GI Dynamics audit committee. Thompson, a chartered accountant, is also NED of Nexstim Limited, a medical technology company quoted on Nasdaq First North Finland and Nasdaq First North Sweden, NED of Novacyt SA, a diagnostic company, listed on Euronext, and is the chair of Premier Veterinary Group plc, the London Stock Exchange listed provider of services to third-party veterinary practices.

  • Business Wire3 months ago

    GI Dynamics Welcomes New Members to Its Scientific Advisory Board

    BOSTON & SYDNEY--(BUSINESSWIRE)-- View source version on businesswire.com: http://www.businesswire.com/news/home/20170813005038/en/

  • Business Wire3 months ago

    GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics ® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier ® in Europe, the Middle East and South America for patients with type 2 diabetes ...

  • Business Wire4 months ago

    GI Dynamics Selects Proven Process Medical Devices as Contract Manufacturer

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics® Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced the selection of Proven Process Medical Devices, Inc. (PPMD) as its contract manufacturing partner. PPMD is one of the nation’s leading designers and manufacturers of Class II and Class III medical devices.

  • Business Wire5 months ago

    GI Dynamics Announces Additional Members to Its Scientific Advisory Board

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics® Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Francesco Rubino, MD, and Philip Schauer, MD have joined the GI Dynamics SAB. The GI Dynamics SAB was designed to advance the body of evidence and state of patient care through EndoBarrier utilization.

  • Business Wire5 months ago

    GI Dynamics Announces $5m Convertible Note Financing with Crystal Amber Fund

    GI Dynamics conducted the financing solely with its major shareholder, Crystal Amber Fund Limited. The financing is intended to provide GI Dynamics with adequate working capital through the remainder of 2017. In connection with the financing, GI Dynamics has been granted a waiver from ASX Listing Rule 10.1 to facilitate the security arrangements.

  • Business Wire5 months ago

    First Data Derived from ABCD Worldwide EndoBarrier Registry Presented at ADA Shows Sustained Metabolic Improvements in Patients with Obesity and Type 2 Diabetes at Six Months Post-explant

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics ® , Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier ® in Europe for patients with type 2 diabetes and obesity, today announced ...

  • Business Wire6 months ago

    GI Dynamics Releases EndoBarrier Re-Implantation Data from German Diabetes Congress

    BOSTON & HAMBURG--(BUSINESSWIRE)-- GI Dynamics ® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier ® in Europe, the Middle East, and South America for patients with type 2 diabetes ...

  • Business Wire6 months ago

    GI Dynamics Announces Change to Board of Directors

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, announces today that the board of directors has received the resignation of GI Dynamics non-executive director Mike Carusi of Advanced Technology Ventures (ATV) and Lightstone Ventures (LSV). “Mike has served on the board of GI Dynamics since 2004, and we thank him for his significant contributions and many years of service,” said Dan Moore, chairman of the board. “After more than a decade serving as a director, and in light of my other numerous commitments with ATV and LSV, I have decided to step down from the board of GI Dynamics,” said Carusi.

  • Business Wire6 months ago

    Meta-Analysis Show EndoBarrier Improves Glycemic Control, Induces Weight Loss in Patients with Type 2 Diabetes and Obesity

    CHICAGO--(BUSINESSWIRE)-- GI Dynamics ® , Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier ® in Europe, the Middle East and South America for patients with type 2 diabetes and ...

  • Business Wire6 months ago

    GI Dynamics Announces Access to 2017 Annual Meeting of Stockholders and Corporate Update

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics ® , Inc. (ASX:GID) (the Company) will hold its 2017 Annual Meeting of Stockholders on 22 May 2017, at 6:00 p.m., United States Eastern Daylight Time, (23 May ...

  • Business Wire6 months ago

    GI Dynamics Announces EndoBarrier CE Mark Suspension

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News) today announced that it received notification from its notified body SGS United Kingdom Limited (SGS) that the CE Mark for its EndoBarrier® system has been suspended pending closure of nonconformances related to its quality management system required under ISO 13485:2003 and 93/42/EEC. “This action does not call the safety and efficacy of EndoBarrier into question and this action does not constitute a recall,” said Scott Schorer, CEO and president.

  • Business Wire6 months ago

    GI Dynamics Announces Scientific Advisory Board Members to Further Development of EndoBarrier

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, has announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Ricardo Cohen, MD, and Christopher Thompson, MD, MHES, have joined the GI Dynamics SAB. The GI Dynamics SAB was created to further advance the body of evidence regarding EndoBarrier and advance the state of patient care with EndoBarrier.

  • Business Wire7 months ago

    GI Dynamics Announces EndoBarrier Data to be Presented at Digestive Disease Week

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics ® , Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier ® in Europe, the Middle East and South America for patients with type 2 diabetes ...

  • Business Wire7 months ago

    GI Dynamics Selects Allenby Capital to Explore AIM Listing Option

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited’s engagement to explore options for seeking admission of GI Dynamics shares to trade on the London Stock Exchange’s AIM market. Allenby Capital is a London-based NOMAD (nominated adviser) and broker on the London Stock Exchange’s AIM market that focuses on providing a range of advisory and transactional services to growing businesses. Allenby Capital has played a leading role in numerous successful listings and secondary fundraisings for its corporate clients in various business sectors and geographical jurisdictions.

  • Business Wire8 months ago

    GI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe and the Middle East for patients with type 2 diabetes and obesity, announced that it will release its 2016 Annual Report on Form 10K on or before 31 March EDT | 1 April AEDT 2017. The webcast and presentation, which will provide a financial update on GI Dynamics, can be accessed at https://event.webcasts.com/starthere.jsp?ei=1141206 or on the GI Dynamics website, www.gidynamics.com, by clicking on the Investor Relations tab and going to the Events and Webcasts page. GI Dynamics, Inc. (ASX:GID.AX - News), is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity.

  • Business Wire8 months ago

    GI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Manoel Galvao Neto, M.D., and David E. Cummings, M.D., have joined the GI Dynamics SAB. The GI Dynamics SAB was created to further advance the body of evidence regarding EndoBarrier, ask and answer relevant questions about treatment using EndoBarrier, and advance the state of patient care with EndoBarrier.

  • Business Wire9 months ago

    GI Dynamics Announces New Scientific Advisory Board and Board’s First Two Members

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced the creation of the GI Dynamics Scientific Advisory Board (SAB). The GI Dynamics SAB will endeavor to bring together distinguished physicians and scientists specializing in endocrinology, gastroenterology and metabolic surgery to advance the evidence-based understanding of EndoBarrier and support its optimal usage. Professor Carel Le Roux, MD, PhD and Professor Jan Willem Greve, MD, PhD, are the first two members to join the SAB.

  • Business Wire9 months ago

    EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, today announced that ...

  • Business Wire10 months ago

    EndoBarrier® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics, Inc., (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, announces that InEk, the German Institute for the Hospital Remuneration System, has awarded EndoBarrier NUB1 Status 1 for 2017. The NUB process allows for introduction of new and innovative medical devices prior to reaching reimbursement eligibility, and provides for a supplemental payment for new technologies in the German reimbursement system. NUB Status 1 is the highest of four levels, as it allows for full reimbursement for the 143 participating hospitals in 2017.

  • Business Wire10 months ago

    GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics, Inc., (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar year with the company’s new management team following the 2016 appointment of Scott Schorer as president and CEO. Schorer subsequently appointed industry veteran Jim Murphy as chief financial officer and Brian Callahan as chief compliance officer to help usher in a new era and re-establish key corporate priorities in driving commercial growth of EndoBarrier®, the first endoscopically-delivered device therapy for the treatment of type 2 diabetes and obesity.

  • noodls11 months ago

    GI Dynamics Board Changes

    Boston, United States Sydney, Australia January 5, 2017 AEDT Investor Relations United States: Monica Bellevue Investor Relations +1 (781) 357-3246 GI DYNAMICS, INC., APPOINTS OERN R. STUGE, MD, AMID CHANGE ...